◎ Sugi Atlas

Atlas / Disease / Ocular hypertension

Ocular hypertension

disease
On this page

Summary

Ocular hypertension (MONDO:0006875) is a disease with 40 GWAS associations across 1 studies and 537 clinical trials. Top therapeutic interventions include timolol, latanoprost, and brimonidine. A subtype of hypertensive disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • GWAS associations: 40
  • Clinical trials: 537

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameocular hypertension
Mondo IDMONDO:0006875
EFOEFO:1001069
MeSHD009798
DOIDDOID:9282
ICD-10-CMH40.05
ICD-11535283437
SNOMED CT4210003
UMLSC0028840
MedGen10423
MedDRA10030043
Is cancer (heuristic)no

Data availability: 40 GWAS associations (1 study).

Disease family

This is a subtype of hypertensive disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › hypertensive disorder › ocular hypertension

Related subtypes (11): essential hypertension, secondary hypertension, pulmonary hypertension, early onset hypertension, chemotherapy-induced hypertension, intracranial hypertension, malignant hypertension, kallikrein hypertension, hypertension, pregnancy-induced, resistant hypertension, hypertensive urgency

Genetics & variants

GWAS landscape

40 GWAS associations across 1 studies. Top hits map to 42 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs1174637107e-13DENND5A?
rs7482718617e-13SLC2A9?
rs1446160517e-13TTLL3, RPUSD3?
rs5511908137e-13IL17RC?
rs1416258037e-13CRPPA, CRPPA-AS1?
rs1155155517e-13CFAP61?
rs1179256997e-13DDOST?
rs1437118697e-13TRIM38?
rs5691586307e-13BACH1, GRIK1?
rs3713619777e-13VARS1?
rs3718490307e-13CHD9?
rs795146587e-13CES5A?
rs1418279447e-13TIMELESS?
rs5656530327e-13MARCHF9?
rs1459761117e-13ITGB4?
rs412860077e-13GCFC2?
rs1467463417e-13COL24A1?
rs5294208137e-13TUT7?
rs1443777527e-13KIF20B?
rs3696806017e-13ZNRF4?
rs115446107e-13ANGPTL4?
rs5467256176e-07STX10?
rs5601050206e-07RIOK3?
rs1156494686e-07LDLRAD2?
rs1458812176e-07KRTAP1-5?
rs617449146e-07RIMOC1?
rs1485406556e-07SERHL2, RRP7BP, RRP7BP?
rs355512716e-07TEX14?
rs5778991576e-07GDPD1?
rs5549383236e-07CDH23?

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90244659Badrinarayanan L202200Whole-genome sequencing unravels novel genetic determinants and regulatory pathways associated with triamcinolone acetonide-induced ocular hypertension.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding35
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic5

MAF distribution

BucketVariants
common (>=0.05)5
low_freq (0.01-0.05)0
rare (<0.01)0
unknown35

Functional consequences

ConsequenceCount
missense_variant34
intergenic_variant4
stop_gained1
intron_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs117463710119180793T>A,Cstop_gainedDENND5A7e-13Tier 1: coding
rs74827186149834915T>C,Gmissense_variantSLC2A97e-13Tier 1: coding
rs14461605139842025C>Tmissense_variantTTLL3, RPUSD37e-13Tier 1: coding
rs55119081339933319T>Cmissense_variantIL17RC7e-13Tier 1: coding
rs141625803716216097A>Gmissense_variantCRPPA, CRPPA-AS17e-13Tier 1: coding
rs1155155512020341899G>Amissense_variantCFAP617e-13Tier 1: coding
rs117925699120653676C>G,Tmissense_variantDDOST7e-13Tier 1: coding
rs143711869625983173C>A,Tmissense_variantTRIM387e-13Tier 1: coding
rs5691586302129561789C>A,Tmissense_variantBACH1, GRIK17e-13Tier 1: coding
rs371361977631784644C>G,Tmissense_variantVARS17e-13Tier 1: coding
rs3718490301653304341T>Gmissense_variantCHD97e-13Tier 1: coding
rs795146581655873887G>A,Tmissense_variantCES5A7e-13Tier 1: coding
rs1418279441256428264C>A,G,Tmissense_variantTIMELESS7e-13Tier 1: coding
rs5656530321257758772C>A,Tmissense_variantMARCHF97e-13Tier 1: coding
rs1459761111775742728C>A,Tmissense_variantITGB47e-13Tier 1: coding
rs41286007275702387C>A,Tmissense_variantGCFC27e-13Tier 1: coding
rs146746341185823690G>A,Tmissense_variantCOL24A17e-13Tier 1: coding
rs529420813986301593C>Tmissense_variantTUT77e-13Tier 1: coding
rs1443777521089743821G>A,Tmissense_variantKIF20B7e-13Tier 1: coding
rs369680601195455976G>Amissense_variantZNRF47e-13Tier 1: coding
rs11544610198366002G>Amissense_variantANGPTL47e-13Tier 1: coding
rs5467256171913145320G>A,Cmissense_variantSTX106e-07Tier 1: coding
rs5601050201823477012C>G,Tmissense_variantRIOK36e-07Tier 1: coding
rs115649468121814781C>Amissense_variantLDLRAD26e-07Tier 1: coding
rs1458812171741026813G>A,Cmissense_variantKRTAP1-56e-07Tier 1: coding
rs61744914541912079A>G,Tmissense_variantRIMOC16e-07Tier 1: coding
rs1485406552242560223G>A,Cmissense_variantSERHL2, RRP7BP, RRP7BP6e-07Tier 1: coding
rs355512711758616233G>Cmissense_variantTEX146e-07Tier 1: coding
rs5778991571759267083C>Amissense_variantGDPD16e-07Tier 1: coding
rs5549383231071740922C>Tmissense_variantCDH236e-07Tier 1: coding

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

9 approved, 6 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
BimatoprostApproved (phase 4)
BrinzolamideApproved (phase 4)
LatanoprostApproved (phase 4)
Latanoprostene BunodApproved (phase 4)
Omidenepag IsopropylApproved (phase 4)
PilocarpineApproved (phase 4)
TafluprostApproved (phase 4)
TimololApproved (phase 4)
TravoprostApproved (phase 4)
BetaxololPhase 3 (in late-stage trials)
BrimonidinePhase 3 (in late-stage trials)
DorzolamidePhase 3 (in late-stage trials)
OfloxacinPhase 3 (in late-stage trials)
PrednisolonePhase 3 (in late-stage trials)
TrabodenosonPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): AMA0076, Piclidenoson.

Clinical trials & evidence

Clinical trials

Clinical trials: 537.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE3137
Not specified136
PHASE4106
PHASE2102
PHASE1/PHASE227
PHASE127
PHASE2/PHASE32

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04957329PHASE4RECRUITINGEffect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells
NCT06498440PHASE4NOT_YET_RECRUITINGEfficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT
NCT06848946PHASE4RECRUITINGSafety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
NCT07217678PHASE4RECRUITINGBiomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
NCT07325240PHASE4RECRUITING24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
NCT07588152PHASE4NOT_YET_RECRUITINGImaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
NCT00047606PHASE4TERMINATEDPhase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32
NCT00061503PHASE4COMPLETEDMechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
NCT00140049PHASE4COMPLETEDA 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
NCT00140062PHASE4COMPLETEDEfficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
NCT00143208PHASE4COMPLETEDEvaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
NCT00273429PHASE4COMPLETEDCosopt Versus Xalatan
NCT00273442PHASE4COMPLETEDAssessing Cosopt Switch Patients
NCT00273481PHASE4COMPLETEDCosopt Versus Xalacom
NCT00300079PHASE4COMPLETEDStudy of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension
NCT00304785PHASE4COMPLETEDLatanoprost Versus Fotil
NCT00329095PHASE4COMPLETEDAn Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
NCT00330577PHASE4COMPLETED24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
NCT00372827PHASE4COMPLETEDStudy of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
NCT00440011PHASE4COMPLETEDBimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
NCT00440141PHASE4COMPLETEDBrimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
NCT00457795PHASE4COMPLETED24-hour IOP-lowering Effect of Brimonidine 0.1%
NCT00471068PHASE4TERMINATEDStudy of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension
NCT00471380PHASE4COMPLETEDA Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension
NCT00508469PHASE4COMPLETEDAdherence Assessment With Travalert Dosing Aid
NCT00527592PHASE4COMPLETEDA Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
NCT00539526PHASE4COMPLETEDEvaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
NCT00541242PHASE4COMPLETEDSafety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
NCT00545064PHASE4COMPLETEDDry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)
NCT00647101PHASE4COMPLETEDA Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
NCT00675207PHASE4COMPLETEDComparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs
NCT00698945PHASE4COMPLETEDComparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
NCT00708422PHASE4COMPLETEDEffects of Travatan Z and Xalatan on Ocular Surface Health
NCT00735449PHASE4COMPLETEDComparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects
NCT00744666PHASE4UNKNOWNIntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids
NCT00759239PHASE4COMPLETEDPhase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
NCT00761995PHASE4COMPLETEDSafety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension
NCT00781300PHASE4COMPLETEDIntraocular Pressure With Loteprednol and Dexamethasone
NCT00798759PHASE4COMPLETEDExamination of Ocular Surface Effects With Administration of Travatan Z and XALATAN
NCT00804648PHASE4COMPLETEDPatient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
TIMOLOL4136
LATANOPROST486
BRIMONIDINE459
TRAVOPROST459
BIMATOPROST457
BRINZOLAMIDE436
DORZOLAMIDE418
TAFLUPROST410
NETARSUDIL47
LATANOPROSTENE BUNOD45
APRACLONIDINE43
HYPROMELLOSE42
LOTEPREDNOL ETABONATE42
BETAMETHASONE41
DEXAMETHASONE41
PILOCARPINE41
PREDNISOLONE41
PREDNISOLONE ACETATE41
TRABODENOSON34
AMA007633
RIPASUDIL32
SEPETAPROST32
ANECORTAVE ACETATE31
EPIGALOCATECHIN GALLATE31
PICLIDENOSON31
VEROSUDIL24
BAMOSIRAN23
DE-10422
AL-1218221
EVODENOSON21

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 23

This page pulls from 23 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpdoidefogenccgwasgwas_studyhgncicd10cmicd11meddramedgenmeshmimmondomondochildmondoparentorphanetsctidumls